Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity position, as indicated by the current, quick, and cash ratios, exhibits fluctuations over the observed period. Generally, the ratios demonstrate a degree of volatility, though a slight overall improvement is apparent towards the end of the analyzed timeframe.
- Current Ratio
- The current ratio experienced a gradual decline from 1.48 in March 2022 to a low of 1.28 in March 2023. A subsequent increase was noted, peaking at 1.60 in December 2024, before settling at 1.55 in December 2025. This suggests periods of potentially tightening short-term liquidity followed by improvements in the ability to cover current liabilities with current assets. The most recent values indicate a strengthening current ratio.
- Quick Ratio
- The quick ratio followed a similar pattern to the current ratio, decreasing from 1.06 in March 2022 to 0.78 in June 2023. A recovery began in September 2023, reaching 1.20 in December 2024, and stabilizing at 1.06 in December 2025. The quick ratio’s movements suggest changes in the composition of current assets, specifically the level of inventory relative to current liabilities. The recent increase indicates improved immediate liquidity.
- Cash Ratio
- The cash ratio demonstrated the most pronounced fluctuations. It decreased from 0.62 in March 2022 to 0.48 in June 2023, then increased to 0.83 in December 2024. The ratio concluded the period at 0.65 in December 2025. This indicates a significant variability in the proportion of current assets held as cash, potentially reflecting strategic cash management decisions or operational needs. The recent values suggest a moderate level of cash coverage for immediate liabilities.
Overall, the observed trends suggest a period of liquidity challenges followed by a strengthening of the liquidity position. The increases in all three ratios towards the end of the period indicate improved short-term financial flexibility. However, the volatility observed throughout the period warrants continued monitoring.
Current Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated a declining trend, followed by periods of relative stability and subsequent increases.
- Initial Decline (Mar 31, 2022 – Sep 30, 2022)
- From March 31, 2022, to September 30, 2022, the current ratio decreased from 1.48 to 1.30. This suggests a weakening in the company’s ability to cover its short-term liabilities with its short-term assets during this timeframe. The decline indicates that current liabilities were growing at a faster rate than current assets.
- Stabilization and Subsequent Increase (Dec 31, 2022 – Jun 30, 2023)
- The ratio stabilized slightly at 1.29 at the end of 2022 and then experienced a significant drop to 1.02 by June 30, 2023. This represents the lowest point in the observed period and indicates a potentially concerning level of short-term liquidity. However, the ratio then rebounded to 1.34 by September 30, 2023, and further increased to 1.43 by December 31, 2023, suggesting improved short-term financial health.
- Fluctuations and Final Increase (Mar 31, 2024 – Dec 31, 2025)
- The period from March 31, 2024, to December 31, 2025, showed continued volatility. The ratio decreased to 1.08 by March 31, 2024, before rising to 1.60 by December 31, 2024. This substantial increase suggests a significant improvement in the company’s liquidity position. The ratio continued to fluctuate, reaching 1.55 by December 31, 2025, indicating sustained, though slightly moderated, liquidity.
- Overall Trend
- Despite the interim fluctuations, the current ratio generally trended upwards from its low point in June 2023. The company demonstrated an ability to improve its short-term asset coverage of its short-term liabilities, particularly in the latter part of the observed period. The increase in the ratio from 1.02 to 1.55 suggests a strengthening of the company’s liquidity position.
The observed changes in the current ratio warrant further investigation into the underlying drivers of both current asset and current liability fluctuations to fully understand the company’s short-term financial dynamics.
Quick Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term marketable debt securities | |||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio for the analyzed period demonstrates fluctuations, generally indicating a moderate ability to meet short-term obligations with highly liquid assets. An initial period of relative stability is followed by a decline, then a recovery, and finally, another period of fluctuation.
- Initial Stability (Mar 31, 2022 – Jun 30, 2022)
- The quick ratio remained consistent at 1.06 for two consecutive quarters. This suggests a stable short-term liquidity position during this timeframe.
- Decline and Recovery (Sep 30, 2022 – Dec 31, 2022)
- A slight decrease to 0.96 was observed in the third quarter, followed by a recovery to 0.99 by the end of the year. This indicates a minor weakening in liquidity, which was partially corrected before year-end.
- Further Weakening (Mar 31, 2023 – Jun 30, 2023)
- The quick ratio experienced a more pronounced decline, falling to 0.78 in the second quarter of 2023. This represents the lowest point in the observed period and suggests a significant reduction in the ability to cover immediate liabilities with quick assets.
- Improvement and Fluctuation (Sep 30, 2023 – Dec 31, 2024)
- The ratio rebounded to 0.98 and then 1.06, indicating an improvement in liquidity. However, this was followed by a substantial drop to 0.72 and 0.69 in the first two quarters of 2024. A subsequent increase to 0.82 and then a more significant jump to 1.20 in December 2024 suggests a considerable strengthening of the short-term liquidity position.
- Recent Trend (Mar 31, 2025 – Dec 31, 2025)
- The quick ratio experienced a slight decrease to 1.00, 0.89, and then 1.01. The period concluded with a ratio of 1.06, indicating a return to a level comparable to earlier periods of stability, though with continued fluctuation.
Overall, the quick ratio demonstrates a pattern of variability. While generally above 0.80 for much of the period, the dips below 0.80, particularly in mid-2023 and early 2024, warrant attention. The recent increase to 1.06 at the end of the analyzed period suggests a positive trend, but continued monitoring is advisable.
Cash Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Short-term marketable debt securities | |||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated relative stability, followed by periods of decline and subsequent recovery.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The cash ratio began at 0.62 and experienced a slight decrease to 0.61 by June 30, 2022. A further decline to 0.54 was noted by September 30, 2022, before partially recovering to 0.57 by the end of the year. This initial period suggests a moderate ability to cover current liabilities with immediately available cash.
- 2023 Performance
- The cash ratio continued a downward trend in the first half of 2023, reaching a low of 0.48 by June 30, 2023. A subsequent increase to 0.57 and 0.64 in the following quarters indicated some improvement in the company’s immediate liquidity position. However, the ratio remained below the initial levels observed in 2022.
- Significant Increase and Subsequent Fluctuations (2024-2025)
- A substantial increase in the cash ratio was observed in the first quarter of 2024, rising to 0.83. This was followed by a sharp decline to 0.26 by June 30, 2024, representing the lowest point in the observed period. The ratio then recovered to 0.43 by September 30, 2024, and further increased to 0.64 by December 31, 2024. This volatility suggests significant shifts in the company’s short-term asset and liability management. The trend continued into 2025, with the ratio fluctuating between 0.47 and 0.65, concluding at 0.65 on December 31, 2025.
Overall, the cash ratio demonstrates considerable variability. While the company generally maintains a positive cash ratio, indicating some capacity to meet short-term obligations with cash, the fluctuations highlight potential challenges in consistently maintaining a strong immediate liquidity position. The significant drop in the first half of 2024 warrants further investigation to understand the underlying factors contributing to this decline and the subsequent recovery.